Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma

Table 3 Sensitivity and specificity of alpha-fetoprotein and prothrombin induced by vitamin K absence-II in differentiating hepatocellular carcinoma from nonmalignant chronic hepatitis B

	Sensitivity	Specificity	PPV	NPV
PIVKA-II (mAU/mL)
> 40
HCC vs CHB	73.9%	89.7%	50.7%	96.0%
HCC vs LC	73.9%	90.4%	84.7%	82.8%
> 100
HCC vs CHB	57.3%	98.8%	87.4%	94.2%
HCC vs LC	57.3%	96.8%	82.8%	76.0%
> 125
HCC vs CHB	56.1%	99.2%	90.7%	94.0%
HCC vs LC	56.1%	97.3%	93.6%	75.5%
> 150
HCC vs CHB	52.9%	99.4%	92.2%	93.6%
HCC vs LC	52.9%	97.3%	93.3%	74.2%
AFP (ng/mL)
> 10
HCC vs CHB	67.5%	90.3%	50.0%	95.1%
HCC vs LC	67.5%	82.6%	73.6%	78.0%
> 20
HCC vs CHB	59.9%	94.4%	60.3%	94.3%
HCC vs LC	59.9%	90.0%	81.0%	75.8%
> 200
HCC vs CHB	36.3%	99.3%	87.7%	91.6%
HCC vs LC	36.3%	99.1%	96.6%	68.5%
> 400
HCC vs CHB	29.9%	99.7%	94.0%	90.9%
HCC vs LC	29.9%	100.0%	100.0%	66.6%
Combination1
HCC vs CHB	75.2%	95.4%	69.8%	96.4%
HCC vs LC	75.2%	92.7%	88.1%	83.9%

¹Combination obtained from variable logAFP + 4.61logPIVKA-II. PPV: Positive predictive value; NPV: Negative predictive value; PIVKA-II: Prothrombin induced by vitamin K absence-II; HCC: Hepatocellular carcinoma; CHB: Chronic hepatitis B; LC: Liver cirrhosis; AFP: Alpha-fetoprotein.